Integrating risk profiles for disease progression in the treatment choice for patients with lower urinary tract symptoms/benign prostatic hyperplasia: A combined analysis of external evidence and clinical expertise

M. Speakman, J. Batista, R. Berges, E. Chartier-Kastler, G. Conti, F. Desgrandchamps, K. Dreikorn, Franklin C. Lowe, M. O'Leary, M. Perez, J. Trachtenberg, A. Tubaro, B. Meesen, L. Smets, H. Stoevelaar

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

The RAND appropriateness method was used to explore the relevance of risk factors for disease progression in the treatment choice for patients with lower urinary tract symptoms/benign prostatic hyperplasia (LUTS/BPH). A total of, 12 international experts assessed the appropriateness of various treatments for 243 risk profiles. Highest appropriateness rates were found for α1-adrenoceptor antagonists (68% of profiles) and combination therapy (46%). A large prostate volume was the dominant argument in favour of 5α-reductase inhibitors and combination therapy, but was irrelevant for the choice of surgery. Considerable postvoid residual, severe symptoms and poor maximum flow rate were the most important factors in favour of surgery.

Original languageEnglish (US)
Pages (from-to)369-374
Number of pages6
JournalProstate Cancer and Prostatic Diseases
Volume8
Issue number4
DOIs
StatePublished - Dec 2005
Externally publishedYes

Fingerprint

Lower Urinary Tract Symptoms
Prostatic Hyperplasia
Disease Progression
Therapeutics
Adrenergic Receptors
Prostate
Oxidoreductases

Keywords

  • Benign prostatic hyperplasia
  • Evidence-based medicine
  • Lower urinary tract symptoms
  • RAND appropriateness method
  • Risk factors

ASJC Scopus subject areas

  • Oncology
  • Urology

Cite this

Integrating risk profiles for disease progression in the treatment choice for patients with lower urinary tract symptoms/benign prostatic hyperplasia : A combined analysis of external evidence and clinical expertise. / Speakman, M.; Batista, J.; Berges, R.; Chartier-Kastler, E.; Conti, G.; Desgrandchamps, F.; Dreikorn, K.; Lowe, Franklin C.; O'Leary, M.; Perez, M.; Trachtenberg, J.; Tubaro, A.; Meesen, B.; Smets, L.; Stoevelaar, H.

In: Prostate Cancer and Prostatic Diseases, Vol. 8, No. 4, 12.2005, p. 369-374.

Research output: Contribution to journalArticle

Speakman, M, Batista, J, Berges, R, Chartier-Kastler, E, Conti, G, Desgrandchamps, F, Dreikorn, K, Lowe, FC, O'Leary, M, Perez, M, Trachtenberg, J, Tubaro, A, Meesen, B, Smets, L & Stoevelaar, H 2005, 'Integrating risk profiles for disease progression in the treatment choice for patients with lower urinary tract symptoms/benign prostatic hyperplasia: A combined analysis of external evidence and clinical expertise', Prostate Cancer and Prostatic Diseases, vol. 8, no. 4, pp. 369-374. https://doi.org/10.1038/sj.pcan.4500827
Speakman, M. ; Batista, J. ; Berges, R. ; Chartier-Kastler, E. ; Conti, G. ; Desgrandchamps, F. ; Dreikorn, K. ; Lowe, Franklin C. ; O'Leary, M. ; Perez, M. ; Trachtenberg, J. ; Tubaro, A. ; Meesen, B. ; Smets, L. ; Stoevelaar, H. / Integrating risk profiles for disease progression in the treatment choice for patients with lower urinary tract symptoms/benign prostatic hyperplasia : A combined analysis of external evidence and clinical expertise. In: Prostate Cancer and Prostatic Diseases. 2005 ; Vol. 8, No. 4. pp. 369-374.
@article{2fec3623380f487abe934e9d2bc1be36,
title = "Integrating risk profiles for disease progression in the treatment choice for patients with lower urinary tract symptoms/benign prostatic hyperplasia: A combined analysis of external evidence and clinical expertise",
abstract = "The RAND appropriateness method was used to explore the relevance of risk factors for disease progression in the treatment choice for patients with lower urinary tract symptoms/benign prostatic hyperplasia (LUTS/BPH). A total of, 12 international experts assessed the appropriateness of various treatments for 243 risk profiles. Highest appropriateness rates were found for α1-adrenoceptor antagonists (68{\%} of profiles) and combination therapy (46{\%}). A large prostate volume was the dominant argument in favour of 5α-reductase inhibitors and combination therapy, but was irrelevant for the choice of surgery. Considerable postvoid residual, severe symptoms and poor maximum flow rate were the most important factors in favour of surgery.",
keywords = "Benign prostatic hyperplasia, Evidence-based medicine, Lower urinary tract symptoms, RAND appropriateness method, Risk factors",
author = "M. Speakman and J. Batista and R. Berges and E. Chartier-Kastler and G. Conti and F. Desgrandchamps and K. Dreikorn and Lowe, {Franklin C.} and M. O'Leary and M. Perez and J. Trachtenberg and A. Tubaro and B. Meesen and L. Smets and H. Stoevelaar",
year = "2005",
month = "12",
doi = "10.1038/sj.pcan.4500827",
language = "English (US)",
volume = "8",
pages = "369--374",
journal = "Prostate Cancer and Prostatic Diseases",
issn = "1365-7852",
publisher = "Nature Publishing Group",
number = "4",

}

TY - JOUR

T1 - Integrating risk profiles for disease progression in the treatment choice for patients with lower urinary tract symptoms/benign prostatic hyperplasia

T2 - A combined analysis of external evidence and clinical expertise

AU - Speakman, M.

AU - Batista, J.

AU - Berges, R.

AU - Chartier-Kastler, E.

AU - Conti, G.

AU - Desgrandchamps, F.

AU - Dreikorn, K.

AU - Lowe, Franklin C.

AU - O'Leary, M.

AU - Perez, M.

AU - Trachtenberg, J.

AU - Tubaro, A.

AU - Meesen, B.

AU - Smets, L.

AU - Stoevelaar, H.

PY - 2005/12

Y1 - 2005/12

N2 - The RAND appropriateness method was used to explore the relevance of risk factors for disease progression in the treatment choice for patients with lower urinary tract symptoms/benign prostatic hyperplasia (LUTS/BPH). A total of, 12 international experts assessed the appropriateness of various treatments for 243 risk profiles. Highest appropriateness rates were found for α1-adrenoceptor antagonists (68% of profiles) and combination therapy (46%). A large prostate volume was the dominant argument in favour of 5α-reductase inhibitors and combination therapy, but was irrelevant for the choice of surgery. Considerable postvoid residual, severe symptoms and poor maximum flow rate were the most important factors in favour of surgery.

AB - The RAND appropriateness method was used to explore the relevance of risk factors for disease progression in the treatment choice for patients with lower urinary tract symptoms/benign prostatic hyperplasia (LUTS/BPH). A total of, 12 international experts assessed the appropriateness of various treatments for 243 risk profiles. Highest appropriateness rates were found for α1-adrenoceptor antagonists (68% of profiles) and combination therapy (46%). A large prostate volume was the dominant argument in favour of 5α-reductase inhibitors and combination therapy, but was irrelevant for the choice of surgery. Considerable postvoid residual, severe symptoms and poor maximum flow rate were the most important factors in favour of surgery.

KW - Benign prostatic hyperplasia

KW - Evidence-based medicine

KW - Lower urinary tract symptoms

KW - RAND appropriateness method

KW - Risk factors

UR - http://www.scopus.com/inward/record.url?scp=30544436072&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=30544436072&partnerID=8YFLogxK

U2 - 10.1038/sj.pcan.4500827

DO - 10.1038/sj.pcan.4500827

M3 - Article

C2 - 16130013

AN - SCOPUS:30544436072

VL - 8

SP - 369

EP - 374

JO - Prostate Cancer and Prostatic Diseases

JF - Prostate Cancer and Prostatic Diseases

SN - 1365-7852

IS - 4

ER -